Understand the source comparison
Cerebrolysin Benefits: Clinical Comparison
Different neuroprotective and neurotrophic compounds show dramatically different efficacy profiles across injury models. The table below compares documented outcomes: | Compound | Primary Mechanism | Stroke Outcome Evidence | TBI Outcome Evidence | Cognitive E
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Different neuroprotective and neurotrophic compounds show dramatically different efficacy profiles across injury models. The table below compares documented outcomes:
- | Compound | Primary Mechanism | Stroke Outcome Evidence | TBI Outcome Evidence | Cognitive Enhancement (Healthy) | Clinical Availability | Bottom Line ||—|—|—|—|—|—|| Cerebrolysin | Multi-peptide neurotrophic mixture; BDNF/NGF mimetic | Cochrane review: modest mortality reduction, improved functional independence at 90 days (RR 0.89) | 68% good recovery vs 52% control at 6 months in moderate-severe TBI (GCS 5–12) | Minimal evidence; most studies in pathological populations | Prescription in EU/Asia; research-grade available | Strong evidence in acute neurological injury; weak evidence for cognitive enhancement in healthy adults || Citicoline | Choline donor; membrane phospholipid precursor | Meta-analysis: no significant benefit in acute stroke (ICTUS trial negative) | Small positive studies; large RCTs pending | Modest attention/focus improvements in healthy adults (effect size 0.3–0.5) | OTC supplement widely available | Inconsistent stroke evidence despite early promise; better saf
- The comparison reveals a consistent pattern: compounds with the strongest clinical evidence (Cerebrolysin, citicoline) have the longest research histories and largest trial populations, while newer synthetic peptides remain preclinical or rely on geographically isolated study populations. Cerebrolysin benefits are documented through imaging-confirmed endpoints (infarct volume, functional MRI) and standardized neurological scales rather than subjective self-reports. A higher evidence standard than most nootropic compounds achieve.